Liquid biopsy offers noninvasive DNA testing for cancer care
Answers from the Lab
DNA tumor testing is key to providing individualized cancer treatment. In this test specific episode of the "Answers From the Lab" podcast, Gang Zheng, M.D., Ph.D., and Aaron Mansfield, M.D., describe Mayo Clinic Laboratories’ liquid biopsy, which detects single nucleotide variants, insertions and deletions in the 33 target genes listed in guidelines. The assay also assesses gene amplifications, translocations and microsatellite instability.
"NGS testing using tissue biopsies is considered a gold standard. But liquid biopsy can also capture tumor heterogeneity and has some advantages over cell-based testing," Dr. Zheng says.
Liquid biopsy can be a more viable option for certain individuals. "Patients might be anticoagulated or have disease in a location that's difficult to stick a needle into," Dr. Mansfield says. "If the disease is primarily metastatic to the bone, decalcifying those specimens might degrade the DNA, making it inappropriate for processing."
Dr. Mansfield notes that many of the genetic mutations included in the liquid biopsy panel —such as RET, ALK fusion and BRAF V600E mutation — have associated therapies approved by the Food and Drug Administration.
Liquid and cell-based biopsies complement each other in patient care. "This liquid biopsy test will enhance the genomic profiling capability of our lab," Dr. Zheng says. "The DNA assay offers our physicians and their patients a noninvasive, comprehensive mutation-profiling option to guide clinical treatment."
Listen to learn more about Mayo Clinic Laboratories' liquid biopsy for cancer care.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Additional Information: Only blood collected in Streck Cell-Free DNA BCT tubes will be accepted for analysis. Whole blood will be processed to produce platelet-poor plasma before cfDNA isolation.
Analytic time: 7 days
Days performed: Monday through Friday
Cristiane (Cris) Ida, M.D., explains how Mayo Clinic Laboratories' updated neuro-oncology gene panel provides more clinically relevant information for managing adult and pediatric brain tumors.
Melissa Snyder, Ph.D., explains how Mayo Clinic Laboratories' EDN panel improves the evaluation of certain patients with asthma and autoimmune digestive disorders. EDN is the first laboratory test that provides a marker of eosinophil-derived neurotoxins.
Gang Zheng, M.D., Ph.D., and Aaron Mansfield, M.D., describe Mayo Clinic Laboratories’ liquid biopsy, which analyzes blood samples for genetic information to guide cancer treatment. The circulating tumor DNA assay uses next generation sequencing and complements the laboratory's cell-based cancer testing.